

FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/FF150E98665EN.html>

Date: July 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: FF150E98665EN

Abstracts

FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

FibroGen Inc (FibroGen) is a biopharmaceutical company that discovers, and develops medicines for the treatment of anemia, cancer, and fibrotic disease. Its approved product includes roxadustat for the treatment of treatment of anemia associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. Its pipeline product includes pamrevlumab (FG-3019) for the treatment of idiopathic pulmonary fibrosis (IPF), duchenne muscular dystrophy (DMD); FG-5200 for the treatment of Corneal Blindness. The company is also evaluating pamrevlumab in Phase II for investigating its safety and efficiency in patients with COVID-19. The company has operations in the US, Hong Kong, Finland, Cayman Islands and China. FibroGen is headquartered in San Francisco, California, the US.

FibroGen Inc Key Recent Developments

Jul 12,2021: FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

May 10,2021: FibroGen Reports First Quarter 2021 Financial Results

Mar 01,2021: FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 18,2021: FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

Dec 01,2020: FibroGen announces retirement of K. Peony Yu, M.D., and appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

FibroGen Inc - Key Facts
FibroGen Inc - Key Employees
FibroGen Inc - Key Employee Biographies
FibroGen Inc - Major Products and Services
FibroGen Inc - History
FibroGen Inc - Company Statement
FibroGen Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
FibroGen Inc - Business Description
Business Segment: Development and Other Revenue
Overview
Performance
Business Segment: License Revenue
Overview
Performance
Business Segment: Product Revenue
Overview
Performance
Geographical Segment: All other
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
R&D Overview
FibroGen Inc - Corporate Strategy
FibroGen Inc - SWOT Analysis
SWOT Analysis - Overview

FibroGen Inc - Strengths
FibroGen Inc - Weaknesses
FibroGen Inc - Opportunities
FibroGen Inc - Threats
FibroGen Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
FibroGen Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 12, 2021: FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer
May 10, 2021: FibroGen Reports First Quarter 2021 Financial Results
Mar 01, 2021: FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 18, 2021: FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
Dec 01, 2020: FibroGen announces retirement of K. Peony Yu, M.D., and appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer
Nov 05, 2020: FibroGen reports third quarter 2020 financial results
Sep 08, 2020: FibroGen appoints Percy Carter, MBA, PhD, as Chief Scientific Officer
Aug 06, 2020: FibroGen announces new appointments to its board of directors
Aug 06, 2020: FibroGen reports second quarter 2020 financial results
Jul 22, 2020: Fibrogen and Blade Therapeutics antifibrotic drug evaluations with COVID19 endpoints draw expert support over trials for Roche and Boehringer Ingelheim’s drugs using standard IPF measures

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

FibroGen Inc, Key Facts
FibroGen Inc, Key Employees
FibroGen Inc, Key Employee Biographies
FibroGen Inc, Major Products and Services
FibroGen Inc, History
FibroGen Inc, Subsidiaries
FibroGen Inc, Key Competitors
FibroGen Inc, Ratios based on current share price
FibroGen Inc, Annual Ratios
FibroGen Inc, Annual Ratios (Cont...1)
FibroGen Inc, Interim Ratios
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
FibroGen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

FibroGen Inc, Performance Chart (2016 - 2020)

FibroGen Inc, Ratio Charts

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/FF150E98665EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FF150E98665EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970